top
Search terms
Results 1 - 10 of 18 - ordered by :
Pages: 1 2
Ejhf

The incremental prognostic and clinical value of multiple novel biomarkers in heart failure Introduction An accurate means of predicting the risk of mortality in heart failure (HF) would allow ...

European Journal of Heart Failure, Jackson, Colette E., Haig, Caroline, Welsh, Paul, Dalzell, Jonathan R., Tsorlalis, Ioannis K., McConnachie, Alex, Preiss, David, Anker, Stefan D., Sattar, Naveed, ...

Date : 01/12/2016 Item size : 160230 bytes
Ejhf

Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I‐PRESERVE) trial Introduction The prognostic ...

European Journal of Heart Failure, Cannon, Jane A., Shen, Li, Jhund, Pardeep S., Anand, Inder S., Komajda, Michel, McKelvie, Robert S., Zile, Michael R., Carson, Peter E., McMurray, John J.V.

Date : 01/08/2016 Item size : 196742 bytes
Ejhf

Aims The use of an erythropoesis-stimulating agent, darbepoetin alfa (DA), to treat anaemia in patients with diabetes mellitus and chronic kidney disease was associated with a heightened risk of ...

European Journal of Heart Failure, Bello, Natalie A., Lewis, Eldrin F., Desai, Akshay S., Anand, Inder S., Krum, Henry, McMurray, John J.V., Olson, Kurt, Solomon, Scott D., Swedberg, Karl, van ...

Date : 01/11/2015 Item size : 53963 bytes
Ejhf

Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease [5] In the Trial to Reduce Cardiovascular Events With Aranesp Therapy ...

European Journal of Heart Failure, Bello, Natalie A., Lewis, Eldrin F., Desai, Akshay S., Anand, Inder S., Krum, Henry, McMurray, John J.V., Olson, Kurt, Solomon, Scott D., Swedberg, Karl, van ...

Date : 01/11/2015 Item size : 151336 bytes
Ehjournal

Methods and results We followed 8561 patients with T2DM and evidence of chronic kidney disease, CV disease, or both in ALTITUDE until the first non-fatal CV or renal event of myocardial infarction ...

European Heart Journal, Jhund, Pardeep S., McMurray, John J.V., Chaturvedi, Nish, Brunel, Patrick, Desai, Akshay S., Finn, Peter V., Haffner, Steven M., Solomon, Scott D., Weinrauch, Larry A., ...

Date : 21/09/2015
Ehjournal

Methods and results We followed 8561 patients with T2DM and evidence of chronic kidney disease, CV disease, or both in ALTITUDE until the first non-fatal CV or renal event of myocardial infarction ...

European Heart Journal, Jhund, Pardeep S., McMurray, John J.V., Chaturvedi, Nish, Brunel, Patrick, Desai, Akshay S., Finn, Peter V., Haffner, Steven M., Solomon, Scott D., Weinrauch, Larry A., ...

Date : 21/09/2015 Item size : 348560 bytes
Ejhf

Introduction The growing elderly population coupled with a decline in mortality from myocardial infarction (MI) has seen the number of patients with heart failure (HF) secondary to coronary artery ...

European Journal of Heart Failure, Badar, Athar A., Perez‐Moreno, Ana C., Hawkins, Nathaniel M., Brunton, Alan P.T., Jhund, Pardeep S., Wong, Chih M., Solomon, Scott D., Granger, Christopher B., ...

Date : 01/02/2015 Item size : 168322 bytes
Ejhf

Introduction The growing elderly population coupled with a decline in mortality from myocardial infarction (MI) has seen the number of patients with heart failure (HF) secondary to coronary artery ...

European Journal of Heart Failure, Badar, Athar A., Perez‐Moreno, Ana C., Hawkins, Nathaniel M., Brunton, Alan P.T., Jhund, Pardeep S., Wong, Chih M., Solomon, Scott D., Granger, Christopher B., ...

Date : 01/02/2015 Item size : 174250 bytes
Ehjournal

See page 2246 for the editorial comment on this article (doi:10.1093/eurheartj/ehs129) Introduction Multiple randomized trials have shown that HMG-CoA reductase inhibitors (statins) reduce morbidity ...

European Heart Journal, Gullestad, Lars, Ueland, Thor, Kjekshus, John, Nymo, Ståle H., Hulthe, Johannes, Muntendam, Pieter, Adourian, Aram, Böhm, Michael, van Veldhuisen, Dirk J., Komajda, ...

Date : 01/09/2012
Ehjournal

Improvement in glycaemic control is no longer an acceptable surrogate for efficacy (or safety) with regard to cardiovascular outcomes.35 Safety must be formally demonstrated in adequately powered ...

European Heart Journal, Zannad, Faiez, Stough, Wendy Gattis, Pocock, Stuart J., Sleight, Peter, Cushman, William C, Cleland, John G.F., McMurray, John J.V., Lonn, Eva, Geller, Nancy L., Wedel, Hans, ...

Date : 01/05/2012 Item size : 369253 bytes